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Background: Patients undergoing percutaneous coronary intervention (PCI) who require
anticoagulant therapy are at increased risk of bleeding. The optimal regimen for these
patients is uncertain. This study aimed to compare safety and efficacy of antithrombotic
regimens used in patients undergoing PCI with concomitant anticoagulant therapy.
Methods: A systematic review and network meta-analysis was performed among
studies comparing antithrombotic regimens for anticoagulated patients undergoing
PCI. The primary outcome of interest was major bleeding. The secondary outcomes
were coronary events. The reference intervention was classic triple therapy (aspirin
plus clopidogrel plus VKA). Cluster rank incorporating risk (major bleeding) and benefit
(all-cause death) was performed to identify the most appropriate regimen(s).
Results: There were 3 RCTs (6 interventions) and 29 non-RCTs (8 interventions) that
met the inclusion criteria with 22,179 patients. Network meta-analysis of RCTs indicated
that dual therapy (DT), either with vitamin K antagonist (VKA) or direct anticoagulant
(DOAC) plus an antiplatelet, significantly reduced the risk of major bleeding compared
to triple therapy (TT) [pooled RR of 0.51 (0.30–0.87) and 0.68 (0.49–0.94), respectively].
In addition, VKA-DT significantly reduced the risk of all-cause death compared to
TT [pooled RR of 0.40 (0.17–0.93)]. Results from network meta-analysis of non-RCT
paralleled that of RCTs. No significant differences of coronary events were found.
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Conclusions: In conclusion, for anticoagulated patients undergoing PCI, dual therapy,
either with warfarin or DOAC plus an antiplatelet, should be considered due to its optimal
balance on efficacy and safety.
Keywords: anticoagulants, antithrombosis, myocardial infarction, network meta-analysis, percutaneous coronary
intervention
INTRODUCTION
Among patients who have an indication for anticoagulant
therapy, approximately one third concurrently suffer from
coronary artery disease where percutaneous coronary
intervention (PCI) may be indicated (Dewilde et al., 2014).
This situation therefore leads to a need for the concomitant
use of both antiplatelet(s) and anticoagulant therapy which
poses heighten risk of major bleeding (Rubboli et al., 2014a).
A recent national registry suggested that the rates of fatal or
nonfatal bleeding among atrial fibrillation patients admitted
with myocardial infarction or for PCI significantly increased
with increasing intensity of anti-thrombotic regimens. Patients
receiving triple therapy [(TT): dual antiplatelet therapy (DAPT)
plus an oral anticoagulant] experienced the highest bleeding
rate at 14.2 events per 100 person-years with adjusted hazard
ratio (HR) of 1.41 compared to dual therapy [(DT): vitamin
K antagonist (VKA) plus single anti-platelet] (Lamberts et al.,
2012). Major bleeding has been shown to increase 1-year
mortality by several folds among PCI patients (Rao et al., 2005;
Manoukian et al., 2007), most likely due to significant blood loss,
hemodynamic compromise, or ischemic events secondary to the
interruption or cessation of anti-thrombotic therapy.
The current situation is even more complex due to increasing
usage of more potent P2Y12 inhibitors, namely prasugrel,
and ticagrelor, and direct oral anticoagulants (DOAC), namely
dabigatran, rivaroxaban, apixaban, and edoxaban. Unfortunately,
direct head-to-head trials comparing efficacy and safety of these
combinations are very limited despite the magnitude of the
problem. Current practice guidelines are therefore based on
limited data and expert consensus, recommending the use of a
TT with aspirin, clopidogrel and an oral anticoagulant as the
standard therapy. DT with clopidogrel and an oral anticoagulant
is also recommended as an alternative for patients in whom
the bleeding risk outweighs the ischemic risk (Kirchhof et al.,
2016; Levine et al., 2016; Roffi et al., 2016; Valgimigli et al.,
2018). However, recommendations regarding the use of newer
Abbreviations: A+C, Aspirin + Clopidogrel; A+C+LMWH, Aspirin +
Clopidogrel + Low-molecular weight heparin; A+C+r, Aspirin + Clopidogrel
+ Rivaroxaban 5mg twice daily; A+C+VKA, Aspirin + Clopidogrel + Vitamin
K antagonist; A+P+VKA, Aspirin + Prasugrel + Vitamin K antagonist;
A+T+VKA, Aspirin + Ticagrelor + Vitamin K antagonist; A+VKA, Aspirin
+ Vitamin K antagonist; BARC, Bleeding Academic Research Consortium;
C+D, Clopidogrel + Dabigatran 150mg twice daily; C+d, Clopidogrel +
Dabigatran 110mg twice daily; C+R, Clopidogrel + Rivaroxaban 15mg once
daily; C+VKA, Clopidogrel + Vitamin K antagonist; DT, Dual therapy (single
antiplatelet + single anticoagulant); SUCRA, The Surface Under the Cumulative
Ranking curve; T+VKA, Ticagrelor + Viatamin K antagonist; TT, Triple therapy
(dual antiplatelet+ single anticoagulant).
antiplatelets and anticoagulants as a part of these regimens are
still limited. We therefore performed a systematic review and
network meta-analysis, where possible, to evaluate the relative
efficacy and safety among various antithrombotic regimens.
METHODS
Study Design
This study was conducted following the registered protocol with
PROSPERO (CRD 42017052655) and was reported according to
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) extension statement for network meta-
analysis (Hutton et al., 2015). The study protocol was approved
by the Institutional Review Board of Mahidol University
(COE.No. MU-DT/PY-IRB 2017/022.2906).
Search Strategy and Study Selection
Relevant studies were identified from MEDLINE (via
PubMed), Embase, Cochrane Central Register of Control Trials
(CENTRAL) and ClinicalTrials.gov since inception to October
1, 2017 the following search terms were used: “PCI,” stent, “acute
coronary syndrome,” “myocardial infarction,” revascularization,
anticoagulant, antithrombotic, “dual antithrombotic,” “P2Y12
receptor antagonist∗,” generic and trade names of antithrombotic
agents (coumarins, warfarin, dabigatran, rivaroxaban, apixaban,
edoxaban, aspirin, clopidogrel, prasugrel, ticagrelor), and
synonymous words. Search strategies were described in
Supplementary Appendix 1. Two investigators (W.B. and P.J.)
independently performed the study selection. The reviewers
independently screened titles and abstracts. Discrepancies
were resolved by discussion. Reference lists of selected articles
were also reviewed, and efforts to contact authors were made
to obtain further study details. Both randomized controlled
trials (RCTs) and non-RCTs were considered without language
restrictions using the following criteria: (1) studied in patients
who underwent PCI and received anticoagulants for prevention
or treatment of thromboembolic complications (2) compared
efficacy and safety among any pair of antithrombotic regimens
(DAPT, DT (aspirin or a P2Y12 receptor antagonist plus an
anticoagulant), and TT (aspirin plus a P2Y12 receptor antagonist
plus an anticoagulant). Studies were excluded if the period of
outcome measurement was <1 month.
Data Extraction and Quality Assessment
Data were extracted including study design, baseline
characteristics (e.g., age, underlying diseases, details of
PCI procedure, and indications of anticoagulant therapy),
antithrombotic regimens both in terms of composition and drug
utilization, and outcomes of interest. Authors were contacted
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in case of incomplete or unclear data. Quality of studies was
assessed depending on type of studies. For RCTs, the Cochrane
Collaboration’s tool for assessing risk of bias (ROB) was used
(Higgins et al., 2016). This tool is comprised of 5 domains
addressing biases in the randomization process, deviations from
intended interventions, missing outcome data, measurement of
the outcome, and selection of the reported result. Meanwhile,
the ROB in Non-randomized Studies tool (ROBINS-I) was used
for non-RCTs. ROBINS-I is comprised of 7 domains addressing
biases due to confounding, selection of participants, classification
of interventions, deviations from intended interventions, missing
data, measurement of outcomes and selection of the reported
result (Sterne et al., 2016).
Type of Interventions and Reclassification
of Regimens
Treatment regimens were combinations within/between drug
classes including antiplatelet agents [aspirin (A), clopidogrel
(C), ticagrelor (T), prasugrel (P)], and anticoagulants [VKA
(e.g., warfarin, acenocoumarol, phenprocoumon), low molecular
weight heparin (LMWH), dabigatran 150mg BID (D), dabigatran
110mg BID (d), rivaroxaban 15mg OD (R), and rivaroxaban
2.5mg BID (r)]. In addition, we reclassified these intervention
into groups based on composition of regimens (Table 1). For
RCT, we were able to classify regimens into 3 groups including
TT (aspirin plus clopidogrel plus a VKA), VKA-DT (aspirin
or a P2Y12 receptor antagonist plus a VKA) and DOAC-
DT (aspirin or a P2Y12 receptor antagonist plus rivaroxaban
or dabigatran). The reclassification is based on differences in
the pharmacological profiles of anticoagulants (between VKAs
vs. direct acting oral anticoagulants) and the intensity of
antithrombotic therapy (TT vs. DT). We excluded two regimens
of RCT from analysis. First was the regimen of aspirin plus
clopidogrel plus 2.5mg BID dose of rivaroxaban from PIONEER-
AF PCI trial since this dose was an unapproved dose for stroke
prevention (Gibson et al., 2016). Second, we extracted data from
clopidogrel plus dabigatran 150mg BID and its corresponding
control arm but not from the 110mg BID arms of the REDUAL-
PCI trial. This was due to the fact that the control arm of each
dabigatran dose was from the same pool of patient population
with some adjustment in number and characteristics of the
patients. If we included the data from both doses, it may create
duplication of control arms (Cannon et al., 2017). We therefore
chose to extract data from dabigatran 150mg BID which is the
most commonly approved dose worldwide. For non-RCT, based
on the available data, we were able to reclassify interventions
into 4 regimens including TT (aspirin plus clopidogrel plus an
anticoagulant), newP2Y12TT (aspirin plus either prasugrel or
ticagrelor plus an anticoagulant), VKA-DT (aspirin or a P2Y12
receptor antagonist plus a VKA), and DAPT (aspirin plus a
P2Y12 receptor antagonist). With these reclassified regimens, we
were able to evaluate the effects of newer antithrombotic therapy
compared to the conventional regimens, which may potentially
extend our knowledge beyond current clinical practice guidelines
(Kirchhof et al., 2016; Levine et al., 2016; Roffi et al., 2016;
Valgimigli et al., 2018).
TABLE 1 | Detail of re-classified regimens.
Regimens Principle Expected
combinations
NewP2Y12-based
TT
Aspirin plus
prasugrel/ticagrelor plus
anticoagulant
A+P+VKA,
A+T+VKA
VKA-based TT
(reference therapy)
aspirin plus P2Y12 receptor
antagonist plus
anticoagulant
A+C+VKA
DOAC-based TT Aspirin plus any P2Y12
receptor antagonist plus
dabigatran/rivaroxaban/
apixaban/edoxaban
A+C+D,
A+C+R,
A+C+apixaban,
A+C+edoxaban
Dual therapy aspirin or P2Y12 receptor
antagonist plus any
anticoagulant (VKA/DOACs)
C+VKA, P+VKA, T+VKA,
C+D/R/apixaban/edpxaban,
P+D/R/apixaban/edpxaban,
T+D/R/apixaban/edpxaban
Dual antiplatelet Aspirin plus any P2Y12
receptor antagonist
A+C,
A+P,
A+T
A, Aspirin; C, Clopidogrel; D, Dabigatran; DOACs, Direct-acting oral anticoagulants; P,
Prasugrel; T, Ticagrelor; TT, Triple therapy; R, Rivaroxaban; VKA, Vitamin K antagonist.
Outcomes of Interest
The primary endpoint was major bleeding which was defined
according to Bleeding Academic Research Consortium (BARC)
type 3–5 (Mehran et al., 2011), and “compatible definition” if
those could be standardized based on BARC type 3–5 criteria (see
details of compatibility criteria in Supplementary Appendix 2).
The secondary endpoints were stroke and/or systemic embolism,
myocardial infarction, repeated revascularization, any stent
thrombosis and all-cause death. In addition, we investigated the
risk-benefit balance of various interventions by incorporating
safety (major bleeding) and efficacy (all-cause death) using
two-dimensional plots and clustering methods to rank these
interventions. All-cause death was used as the efficacy outcome
due to the lack of uniformity in the report of major cardiovascular
events.
Data Synthesis and Statistical Methods
A pairwise meta-analysis and network meta-analysis were
performed as follows. A pairwise meta-analysis, risk ratio (RR)
along with 95% confidence interval (CI) was estimated and
pooled using a random-effects model (DerSimonian and Laird,
1986). Heterogeneity was assessed using Cochrane Q test and
I2 statistics (Maldonado et al., 2009). A network meta-analysis
was performed to compare relative efficacy and safety among
regimens. Relative treatment effects (RR) were estimated for
each comparison vs. a common comparator of A+C+VKA
or TT for re-classified. Subsequently, these RRs were pooled
across studies using a meta-analysis with a consistency model
(Jansen et al., 2011). We used the global inconsistency test to
evaluate inconsistency in a network as a whole. If inconsistency
was detected, we then used the loop-specific and node-splitting
methods to identify which piece of evidence was responsible
for inconsistency (Dias et al., 2010). Adjusted funnel plots were
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produced in order to determine small study effects (Mavridis
and Salanti, 2014). The surface under the cumulative ranking
curve (SUCRA) was performed to rank various antithrombotic
regimens for each outcome. Finally, the cluster rank, a technique
used to combine multidimensional aspects (usually risk and
benefit) of an intervention, was performed to incorporate safety
(major bleeding) and efficacy (all-cause death) simultaneously
(Jinatongthai et al., 2017). The same approaches were used to
compare 5 re-classified regimens including TT, newP2Y12TT,
VKA-DT, DOAC-DT, and DAPT.
FIGURE 1 | Flow diagram and references of included studies.
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Pre-specified subgroup analyses were performed by
patient characteristics (atrial fibrillation and atrial fibrillation
predominant group, follow-up period (<1, 1, >1 year), PCI-
related predominant characteristics [i.e., ACS, elective PCI,
bare-metal stent (BMS), drug-eluting stent (DES)], and study
characteristics (study design and setting). Predominant groups
were classified if characteristic prevalence was ≥50%. A pre-
specified sensitivity analysis was performed on different major
bleeding definitions and certain characteristics of studies (i.e.,
adjusted analysis, multicenter studies, omitting small sample size
studies or serious-to-critical ROB). All analyses were stratified
by non-RCTs and RCTs using STATA 14.0 (Stata Corp, College
Station, TX). A p < 0.05 was considered statistically significant.
RESULTS
Study Selection
Overall, 22,737 records were identified, 258 potentially eligible
articles were retrieved in full text. 200 and 28 articles were
excluded, mostly due to absence of anticoagulant indication
in the control group, contamination of patients without PCI
or unknown rate of PCI, and no outcome of interest. Finally,
30 studies were included in our systematic review including 3
RCTs and 27 non-RCTs. Among 27 non-RCTs, only 23 studies
were included in the quantitative analysis since 3 studies did
not sufficiently specify composition of drug regimens while one
study did not provide adequate outcome data. The PRISMA flow
diagram is shown in Figure 1.
Characteristics and Quality of Included
Studies
A total of 12 antithrombotic regimens were identified including 1
DAPT (A+C), 6 DTs (A+VKA, C+VKA, T+VKA, C+R, C+D,
C+d), and 5 TTs (A+C+VKA, A+P+VKA, A+T+VKA,
A+C+r, A+C+LMWH). Detail of each regimen was
summarized in Supplementary Appendix 3. Characteristics
of all included studies are shown in Table 2.
For 3 RCTs involving 5,412 patients, 1 trial was 2-arm RCT
comparing A+C+VKA vs. C+VKA (Dewilde et al., 2013) while
the others were 3-arm RCT comparing A+C+VKA vs. C+R
vs. A+C+r (Gibson et al., 2016) and A+C+VKA vs. C+D vs.
C+d (Cannon et al., 2017). Study settings, applied treatment
regimens and patient baseline characteristics of these trials
are summarized in Supplementary Appendix 4: eTables 4.1–
4.5. Quality of included RCTs based on Cochrane ROB tool
was assessed, which suggested some concerns with all trials.
Cause of bias in these open-labeled trials was mainly due to lack
of data about protocol deviations (Supplementary Appendix 4:
eTable 4.6).
Among 27 non-RCTs, there was 1 post-hoc analysis of RCT
(Fiedler et al., 2015), 12 prospective cohorts (Sarafoff et al.,
2008, 2013; Valencia et al., 2008; Gilard et al., 2009; Sambola
et al., 2009, 2016; Gao et al., 2010; Rubboli et al., 2012, 2014a,b;
Dabrowska et al., 2013; Choi et al., 2017), and 14 retrospective
cohorts (Nguyen et al., 2007; Maegdefessel et al., 2008; Manzano-
Fernández et al., 2008; Ruiz-Nodar et al., 2008; Jang et al., 2011;
Caballero et al., 2013; Ho et al., 2013; Goto et al., 2014; Suh et al.,
2014; Braun et al., 2015; Hess et al., 2015; Kang et al., 2015; De
Vecchis et al., 2016; Fu et al., 2016). Nineteen studies were 2-
arm (Manzano-Fernández et al., 2008; Ruiz-Nodar et al., 2008;
Sarafoff et al., 2008, 2013; Valencia et al., 2008; Gilard et al., 2009;
Jang et al., 2011; Caballero et al., 2013; Dabrowska et al., 2013; Ho
et al., 2013; Goto et al., 2014; Suh et al., 2014; Braun et al., 2015;
Fiedler et al., 2015; Hess et al., 2015; Kang et al., 2015; Fu et al.,
2016; Sambola et al., 2016; Choi et al., 2017) and 8 studies were 3-
arm comparisons (Nguyen et al., 2007; Maegdefessel et al., 2008;
Sambola et al., 2009; Gao et al., 2010; Rubboli et al., 2012, 2014a,b;
De Vecchis et al., 2016). All studies used A+C+VKA as the
reference. A total of 8 interventions were considered including
A+C, A+VKA, C+VKA, T+VKA, A+C+VKA, A+P+VKA,
A+T+VKA, and A+C+LMWH. Study settings and patient
baseline characteristics of these studies are summarized in
Supplementary Appendix 5: eTables 5.1–5.4. Various patterns
of regimens used were found, especially duration of treatment
(Supplementary Appendix 5: eTable 5.5). Among non-RCTs, 7,
19, 70, and 4% of studies were with low, moderate, serious,
and critical risk, respectively (Supplementary Appendix 5:
eTable 5.6).
Effect on the Primary and Secondary
Outcomes
RCTs
Since there were only 3 RCTs including WOEST, PIONEER
AF-PCI and REDUAL-PCI, meta-analysis on RCTs was not
performed since there were too few trials. However, data from
these trials were extracted and used to compare 3 re-classified
regimens. Results of which are reported in the re-classified
regimen section (Dewilde et al., 2013; Gibson et al., 2016; Cannon
et al., 2017).
Non-RCTs
Results From Pairwise Meta-Analysis
For major bleeding, A+C significantly reduced risk of bleeding
while A+P+VKA increased such risk compared to A+C+VKA
with pooled RR 0.58 (0.40, 0.83) and pooled RR 5.00
(1.52, 16.67), respectively. For stroke, A+C increased risk
of any stroke compared to A+C+VKA, with pooled RR
1.60 (1.04, 2.45). Overall, there was no statistically significant
difference among these regimens in the risk of myocardial
infarction, repeated revascularization, and stent thrombosis.
For all-cause death, A+C+LMWH significantly increased the
risk relative to A+C with pooled RR 4.17 (1.02, 16.67)
(Supplementary Appendix 6).
Results From Network Meta-Analysis
The network of eligible comparisons for the primary
outcome and secondary outcomes are shown in Figure 2.
Global inconsistency was not found in each outcome
(Supplementary Appendix 7). The pooled estimates of all
outcomes were then based on consistency model.
A total of 17 studies (n= 11,961) consisting of 8 interventions
reported major bleeding as BARC type 3–5 or compatible
definitions (Supplementary Appendix 2). Results from network
meta-analysis showed that A+C significantly reduced risk of
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FIGURE 2 | Network maps of treatment options for all outcomes. A+C, aspirin+clopidogrel; A+C+LMWH, aspirin+clopidogrel+low-molecular weight heparin;
A+C+VKA, aspirin+clopidogrel+vitamin K antagonist; A+P+VKA, aspirin+prasugrel+vitamin K antagonist; A+T+VKA, aspirin+ticagrelor+vitamin K antagonist;
A+VKA, aspirin+vitamin K antagonist; C+VKA, clopidogrel+vitamin K antagonist; T+VKA, ticagrelor+vitamin K antagonist.
major bleeding with a pooled RR of 0.57 (0.39–0.84) while
A+P+VKA significantly increased such risk with a pooled
RR of 5.09 (1.10–23.44) when compared to A+C+VKA. For
stroke, network meta-analyses indicated that A+C significantly
increased stroke risk compared to A+C+VKA with the pooled
RR of 1.69 (1.06–2.68), respectively. For myocardial infarction,
repeated revascularization, and stent thrombosis, there was
no statistically significant difference among all regimens in
these outcomes. For all-cause death, network meta-analysis
showed that A+C+LMWH significantly increased risk of all-
cause death compared to C+VKA, pooled RR of 4.55 (1.08,20).
The forest plot for all outcomes compared to the reference
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therapy (A+C+VKA) is shown in Figure 3. Further information
and ranking can be found in Supplementary Appendix 8–9.
For a combination of risk-benefit outcomes, the cluster rank
incorporating major bleeding and all-cause death showed that
A+T+VKA and C+VKA were the best regimens. A+T+VKA
had the lowest mortality risk while C+VKA had the lowest risk of
major bleeding. A+C+LMWH and A+P+VKA were the worst
regimens since A+C+LMWHwas with the highest mortality risk
while A+P+VKA was with the highest risk of major bleeding
(Figure 4).
Re-classified Regimen Analysis
For the 3 available RCTs including WOEST, PIONEER AF-
PCI and REDUAL-PCI (Dewilde et al., 2013; Gibson et al.,
2016; Cannon et al., 2017), we were able to compare 3 re-
classified regimens including TT (A+C+VKA) vs. VKA-DT
(C+VKA) vs. DOAC-DT (C+R, C+D). Results of network
meta-analysis indicated that both VKA-DT and DOAC-DT
significantly reduced the risk of major bleeding compared to TT
[pooled RR of 0.51 (0.30–0.87); p = 0.014 and 0.68 (0.49–0.94);
p = 0.02, respectively]. For stroke, myocardial infarction and
stent thrombosis, there were no significant differences among
these 3 regimens. However, VKA-DT significantly reduced the
risk of all-cause death compared to TT [pooled RR of 0.40 (0.17–
0.93); p = 0.034] (Supplementary Appendix 10). The cluster
rank incorporating major bleeding and all-cause death showed
that VKA-DT was the best regimens (Figure 5).
For 23 non-RCTs, we reclassified 8 interventions into 4 groups
including TT (A+C+VKA, A+C+LMWH), newP2Y12-based
TT (A+P+VKA, A+T+VKA), VKA-DT (A+VKA, C+VKA,
T+VKA), and DAPT (A+C). For major bleeding, SUCRA
ranking showed that DAPT was the best regimen followed by
DT, TT, and newP2Y12-based TT (Supplementary Appendix 11:
eTable 11.1 and eFigure 11.1). Among efficacy outcomes, no
statistical differences were found except increased risk of stroke
from DAPT compared to TT with pooled RR 1.65 (1.08,
2.51) (Supplementary Appendix 11: eTable 11.2, eFigure 11.2).
Based on the cluster rank of risk-benefit outcome, the best
regimen was still VKA-DT in non-RCTs group (Figure 6).
Subgroup Analyses
For primary outcomes, all results from subgroup analyses
(AF predominant group, ACS predominant group, stented
with DES predominant group, and variety of period of
follow-up) were consistent with the results in main analysis
(Supplementary Appendix 12).
Sensitivity Analyses and Publication Bias
Sensitivity analyses with different types of major bleeding
definitions were consistent with the main results
(Supplementary Appendix 13: eTable 13.1). According to
stroke subtypes, analysis showed that A+C reduced risk of
hemorrhagic stroke compared to A+C+VKA and A+P+VKA
with pooled RR 0.38 (0.16, 0.92) and pooled RR 0.02 (0.00,
0.48), respectively. We also performed sensitivity analysis
among studies with adjusted RR, the results was consistent
with main results. Further information from sensitivity
analyses can be found in Supplementary Appendix 13.
There was no clear evidence of small study effect, based on
a lack of asymmetry shown in adjusted funnel plot analysis
(Supplementary Appendix 14).
DISCUSSION
This systematic review and network meta-analysis attempts
to address one of the most controversial issues in the PCI
era. Accessibility of PCI is increasing worldwide, however,
appropriate drug combinations for patients whom anticoagulant
therapy is indicated are still unknown. The current treatment
guidelines recommend the TT of aspirin, clopidogrel and an
oral anticoagulant as the standard therapy (Kirchhof et al.,
2016; Levine et al., 2016; Roffi et al., 2016; Valgimigli et al.,
2018). However, this regimen has been shown to increase the
risk of major bleeding by 40%, and among those who suffered
major bleeding, there were several fold increased in mortality
(Lamberts et al., 2012). The magnitude of this problem is clearly
evident since approximately one third of patients requiring
anticoagulant therapy may require PCI (Dewilde et al., 2014).
Attempts therefore have beenmade to find an alternative regimen
that can prevent both stroke and coronary events while minimize
the risk of bleeding. Based on several RCTs and observational
studies, DT with clopidogrel and an oral anticoagulant has
been shown to reduce bleeding. However, its ability to reduce
both stroke and coronary events is less than certain since all
trials did not have sufficient power to detect differences in
stroke and coronary events. Despite such limitation, the current
practice guidelines still recommend DT as a viable option in
patients with high bleeding risk. In addition, data regarding
the newer antiplatelets and anticoagulants were quite limited at
the time when the guidelines were written. Therefore, a more
comprehensive and updated analysis is needed to answer some
of these issues.
To the best of our knowledge, our study is the first
that compared regimens containing DOACs and new P2Y12
inhibitors using network meta-analysis. In addition, we tried to
overcome the issue of varied bleeding definitions across studies
by matching the definition of bleeding events reported in each
trial with the BARC definition before including those studies
into the primary outcome analysis. We also performed sensitivity
analyses to assess the robustness of our conclusions based on
different major bleeding definitions (Mehran et al., 2011). This
is a key strength of this analysis compared to previous works.
Based on analysis of non-RCTs, A+P+VKA increased risk
of major bleeding compared to most regimens. Furthermore,
A+P+VKA tended to increase risk of hemorrhagic stroke
in sensitivity analysis based on type of stroke. This finding
paralleled the result of the TRITON-TIMI-38 (Wiviott et al.,
2007). Although population and drug regimens in our analysis
and TRITON-TIMI 38 are not identical, caution must be raised
regarding the employment of prasugrel-based regimen.
Our results for both pairwise and network meta-analyses
indicated that A+C showed the lowest risk of major and any
bleedings but it increased risk of stroke (RR = 1.69, 1.06–2.68).
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FIGURE 3 | A forest plot of network meta-analysis of interventions compared with classic triple therapy (A+C+VKA). A+C, aspirin+clopidogrel;
A+C+LMWH, aspirin+clopidogrel+low-molecular weight heparin; A+C+VKA, aspirin+clopidogrel+vitamin K antagonist; A+P+VKA, aspirin+prasugrel+vitamin K
antagonist.
In ACTIVE-W trials, which investigated efficacy of this regimen
vs. warfarin in patients with atrial fibrillation, A+C showed
higher risk of stroke compared to warfarin (RR = 1.44, 1.18–
1.76) (Connolly et al., 2006). Therefore, our result confirms the
beneficial effect of anticoagulant therapy in patients with high
thromboembolic risk.
Although we found no differences among all regimens
in coronary outcomes, A+C+VKA was the most efficacious
regimen in coronary outcomes based on SUCRA ranking. Risk-
benefit outcome incorporating major bleeding and all-cause
death showed that A+T+VKA and C+VKA were the most
appropriate regimens. However, we caution readers to consider
interpreting this finding carefully. The data of A+T+VKA was
based entirely on a small observational study with only 27
patients using this intervention (Fu et al., 2016). In addition,
beneficial effects of C+VKA among non-RCTs parallel the result
of C+VKA in WOEST trial in terms of all-cause death reduction
(Dewilde et al., 2013). As a result, C+VKA may be the best
regimen based on our analysis.
With network meta-analysis and reclassification of
antithrombotic regimens, we were able to perform analysis
on the safety and efficacy of new P2Y12-based TT and
DOACs-DT compared to conventional regimens. Based on
RCTs, we were able to show that DOAC-DT significantly
reduce major bleeding compared to TT and ranked favorably
compared to TT when considering both major bleeding
and all-cause death. Although VKA-DT was ranked best in
risk-benefit outcome, we cautioned readers that this may be
due to different patient characteristics along with types of
antiplatelet used in WOEST compared to other trials. While
all patients in both PIONEER AF-PCI and REDUAL-PCI
were on anticoagulant therapy for at least 1 year, only 90%
of patients in WOEST were on anticoagulant for 1 year.
This may be due to the fact that WOEST trial included
patients who were on anticoagulation for shorter term such
as venous thromboembolism and apical thrombus. With
shorter duration of treatment, bleeding rates may be lower
compared to patients requiring life-long therapy in both
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FIGURE 4 | cluster rank incorporating risk estimate of major bleeding vs. all-cause death outcomes: main analysis (non-RCTs). A+C, aspirin + clopidogrel;
A+C+LMWH, aspirin + clopidogrel + low-molecular weight heparin; A+C+VKA, aspirin + clopidogrel + vitamin K antagonist; A+P+VKA, aspirin + prasugrel +
vitamin K antagonist; A+T+VKA, aspirin + ticagrelor + vitamin K antagonist; A+VKA, aspirin + vitamin K antagonist; C+VKA, clopidogrel + vitamin K antagonist;
T+VKA, ticagrelor + vitamin K antagonist.
FIGURE 5 | Cluster rank incorporating risk estimate of major bleeding vs. all-cause death outcomes: analysis of reclassified regimens among RCTs.
DOAC, Direct-acting oral anticoagulant; DT, Dual therapy; TT, Triple therapy; VKA, Vitamin K antagonist.
PIONEER AF-PCI and REDUAL-PCI trials. In addition, newer
and more potent antiplatelets were used in both PIONEER
AF-PCI and REDUAL-PCI while clopidogrel was exclusively
used in WOEST trial. Both issues may partly explain higher
bleeding rates in PIONEER AF-PCI and REDUAL-PCI. For
non-RCTs, cluster rank indicated that a new P2Y12-based
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FIGURE 6 | Cluster rank incorporating risk estimate of major bleeding vs. all-cause death outcomes: analysis of reclassified regimens among non-RCTs. DAPT, Dual
antiplatelet; DT, Dual therapy; TT, Triple therapy; newP2Y12TT, New P2Y12 inhibitor-based triple therapy; VKA, Vitamin K antagonist.
TT may not be an appropriate option due to higher risk
of both bleeding and all-cause death compared to all other
regimens.
Prior to our study, there were a number of meta-analyses and
one network meta-analysis evaluating the same issue (Bavishi
et al., 2016; Briasoulis et al., 2016; Palla et al., 2016). Results
from pairwise meta-analyses were with conflicting results. This is
most likely due to difference of included studies and definition
of major bleeding in each meta-analysis. For network meta-
analysis, Liu et al. previously compared efficacy and safety of
DAPT, A+VKA, C+VKA, and A+C+VKA (Liu et al., 2016).
Our analysis was different in many aspects. First, we considered
and included newer agents that have become increasingly used
in clinical practice such as new P2Y12 inhibitors and DOACs.
Second, we only included trials which all patients received PCI,
while the previous study included trials which contained some
populations who did not undergo PCI. Finally, previous analysis
accepted major bleeding definition according to the original
articles while we standardized bleeding based on the BARC
definition.
STUDY LIMITATIONS
Our study has several key limitations. First, the majority of
the data included in our analysis came from observational
studies. Therefore, relative treatment effects were susceptible
to the influence of confounding factors. Second, analysis of
baseline characteristics and subgroup analyses were based on
data of study level, not individual patient data level. Therefore,
we could assess the data as “predominant characteristics,”
which mean some contamination existed in some subgroup
analyses. The reclassification of BARC bleeding was also
done at a study level, not patient data level. Thirdly, due
to a sparse number of studies of each combination, except
A+C and A+C+VKA, our results depended mainly upon
indirect comparisons from the network meta-analysis. Some
findings were statistically significant with wide confidence
intervals due to small sample size in each individual study.
Therefore, results of our study are for hypothesis generation
only. Lastly, we were unable to make any adjustment on
the variation of treatment duration of each regimen. This
may introduce heterogeneity on treatment duration of each
regimen since regimen switching cannot be ruled out. Therefore,
we could not avoid contaminating treatment effect at the
point of outcome measurement in many studies. In addition,
lack of information on time in therapeutic range for VKA
therapy in each study may potentially affect the outcome.
These limitations highlight the need for more high quality
evidence for this controversial issue. Currently, there are several
RCT being conducted to assess the efficacy and safety of
DOACs and new P2Y12 inhibitor-based regimen including
AUGUSTUS with apixaban, ENTRUST-AF PCI with edoxaban
and MANJUSRI with ticagrelor (Lu et al., 2015; Vranckx
et al., 2018). Results from these upcoming RCTs will add
more information in the future. Until those high quality data
become available, our systematic review may offer the most
comprehensive data set and provide some guidance to tackle this
issue.
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CONCLUSION
In summary, our analysis shows that dual therapy, either with
VKA or DOAC plus a single antiplatelet, may be an attractive
option for patients with PCI whom anticoagulant are indicated.
DT may offer an optimal balance on safety and efficacy by
lowering risk of bleeding while maintaining antithrombotic
effects both from stroke/systemic embolism and coronary events
post PCI, compared to TT. However, more trials are warranted to
clarify this issue.
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